SCHEMBL3494840

SCHEMBL3494840

Cc1c(CC(=O)O)sc2nc(Cc3ccc(Cl)c(Cl)c3)[nH]c(=O)c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNASEH1 O60930 1/20 0.54
ALDH1A1 P00352 6/20 0.46
KDM4E B2RXH2 5/20 0.46
KMT2A Q03164 2/20 0.46
PDE5A O76074 1/20 0.46
MAPT P10636 3/20 0.46
BRD4 O60885 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
MEN1 O00255 1/20 0.41
LMNA P02545 2/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
POLB P06746 1/20 0.41
PLEC Q15149 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40
DHFR P00374 1/20 0.40
TYMS P04818 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3494138 0.90 RNASEH1 (0.52) RNASEH1ALDH1A1KDM4EKMT2APDE5A
SCHEMBL3491779 0.88 RNASEH1 (0.50) RNASEH1ALDH1A1KDM4EKMT2APDE5A
SCHEMBL3491664 0.85 RNASEH1 (0.58) RNASEH1ALDH1A1KDM4EKMT2APDE5A
SCHEMBL3492896 0.84 RNASEH1 (0.57) RNASEH1ALDH1A1KDM4EKMT2APDE5A
SCHEMBL4521433 0.84 ALDH1A1 (0.46) RNASEH1ALDH1A1KDM4EKMT2APDE5A
SCHEMBL16175762 0.83 RNASEH1 (0.54) RNASEH1ALDH1A1KDM4EKMT2APDE5A
SCHEMBL4517291 0.82 RNASEH1 (0.46) RNASEH1ALDH1A1KDM4EKMT2APDE5A
SCHEMBL38376 0.82 RNASEH1 (0.52) RNASEH1ALDH1A1KDM4EKMT2APDE5A
SCHEMBL3492895 0.81 RNASEH1 (0.51) RNASEH1ALDH1A1KDM4EKMT2APDE5A
SCHEMBL4511602 0.81 HPGD (0.45) RNASEH1ALDH1A1KDM4EKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870656-B2 Methods for treatment of heart failure CARDURION PHARMACEUTICALS, LLC (US) 2020-12-22 US disclosed
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE CARDURION PHARMACEUTICALS LLC (US) 2019-07-11 US disclosed
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD RNASEH1 974/4885ALDH1A1 762/4885KDM4E 4291/4885
US-10870656-B2 Methods for treatment of heart failure TNNT2, TNNI3, TNNC1 RNASEH1 1001/4885ALDH1A1 748/4885KDM4E 3591/4885
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 RNASEH1 813/4885ALDH1A1 2303/4885KDM4E 2859/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 RNASEH1 813/4885ALDH1A1 2303/4885KDM4E 2859/4885
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE TNNT2, TNNI3, TNNC1 RNASEH1 1001/4885ALDH1A1 748/4885KDM4E 3591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.